To present a case of prolonged survival in a patient with EGFR-mutant lung cancer and leptomeningeal metastasis treated with a multimodal approach including erlotinib.
Key Findings:
The patient remained disease-free at the time of publication, with no detectable EGFR mutation via liquid biopsy.
Erlotinib treatment led to regression of leptomeningeal involvement and no evidence of distant disease after two years.
Interpretation:
This case suggests that erlotinib may be effective in managing leptomeningeal carcinomatosis in patients with EGFR mutations, warranting further investigation into optimal treatment regimens.
Limitations:
The study is based on a single case, limiting generalizability.
Lack of control group and randomization.
Conclusion:
Erlotinib, in conjunction with intrathecal chemotherapy and craniospinal radiotherapy, may provide a viable treatment option for patients with leptomeningeal carcinomatosis secondary to EGFR-mutant lung cancer.
